Immunogenicity and safety of a second dose of a measles-mumps-rubella vaccine administered to healthy participants 7  years of age or older: A phase III, randomized study

.

Source: Human Vaccines and Immunotherapeutics - June 14, 2018 Category: Allergy & Immunology Authors: Remon Abu-Elyazeed William Jennings Randall Severance Michael Noss Adrian Caplanusi Michael Povey Ouzama Henry Source Type: research